Bahgat Z Gerges

Dr. Bahgat Z Gerges

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2023 in JAC-Antimicrobial Resistance
Verified
Journal Article
Open access
PDF file
KRKenneth Rolston
Kenneth Rolston
BGBahgat Z Gerges
Bahgat Z Gerges
LNLior Nesher
Lior Nesher
SSSamuel A. Shelburne
Samuel A. Shelburne
RPRandall Prince
Randall Prince
Issam I RaadIssam I Raad
Issam I Raad
Bacterial infections are common in patients with cancer, and many bacteria have developed resistance to currently used antibiotics. We evaluated the in vitro activity of eravacycline (a recently developed fluorocycline) and comparators against bacterial pathogens isolated from patients with cancer. Antimicrobial susceptibility testing was performed using CLSI-approved methodology and interpretive criteria for 255 Gram-positive and 310 Gram-negative bacteria. MIC and susceptibility percentage were calculated according to CLSI and FDA breakpoints when available. Eravacycline had potent activity against most Gram-positive bacteria, including MRSA. Of 80 Gram-positive isolates with available breakpoints, 74 (92.5%) were susceptible to eravacycline. Eravacycline had potent activity against most Enterobacterales, including ESBL-producing organisms. Of 230 Gram-negative isolates with available breakpoints, 201 (87.4%) were susceptible to eravacycline. Eravacycline had the best activity among comparators against carbapenem-resistant Enterobacterales, with 83% susceptibility. Eravacycline was also active against many non-fermenting Gram-negative bacteria, with the lowest MIC90 value among comparators. Eravacycline was active against many clinically significant bacteria isolated from patients with cancer, including MRSA, carbapenem-resistant Enterobacterales, and non-fermenting Gram-negative bacilli. Eravacycline might play an important role in the treatment of bacterial infections in patients with cancer, and additional clinical evaluation is warranted.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
BGBahgat Z Gerges
Bahgat Z Gerges
JRJoel Rosenblatt
Joel Rosenblatt
YTY-Lan Truong
Y-Lan Truong
RRRuth A. Reitzel
Ruth A. Reitzel
RHRay. Y. Hachem
Ray. Y. Hachem
Issam I RaadIssam I Raad
Issam I Raad
Antiseptic wound ointments are widely used to treat dermal wounds that are microbially contaminated. Polygalacturonic acid (PG)+caprylic acid (CAP) is a novel combination that has been shown to eradicate biofilms. We developed a novel PG+CAP ointment and compared the biofilm eradication capability and cytotoxicity of PG+CAP with that of commercially available antiseptic wound ointments. We used a well‐established biofilm model to quantitatively assess the eradication of organisms following exposure to the wound ointments for 2 hours. PG+CAP ointment completely eradicated Candida albicans, multidrug‐resistant Pseudomonas aeruginosa, and methicillin‐resistant Staphylococcus aureus biofilms, whereas MediHoney, polyhexamethylene biguanide (PHMB), and benzalkonium chloride (BZK) ointments failed to eradicate all biofilms within 2 hours. We assessed cytotoxicity by exposing L‐929 fibroblasts to extracts of each ointment; Trypan blue exclusion was used to assess cell viability, and Alamar blue conversion was used to assess metabolic function. After exposure to PG+CAP and MediHoney, fibroblast viability was 96.23% and 95.23%, respectively (Trypan blue), and was comparable to untreated cells (98.77%). PHMB and BZK showed reduced viability (83.25% and 77.83%, respectively, p < 0.05). Metabolic activity results followed a similar pattern. Cytotoxicity of PG+CAP ointment towards erythrocytes was comparable to saline. PG+CAP ointment seems to be safe and can rapidly eradicate microbial biofilm; thus, PG+CAP ointment merits further in vivo testing as a potential antimicrobial wound ointment.

2 March 2023 in JAC-Antimicrobial Resistance
Verified
Journal Article
Open access
PDF file
BGBahgat Z Gerges
Bahgat Z Gerges
KRKenneth Rolston
Kenneth Rolston
SSSamuel A Shelburne
Samuel A Shelburne
JRJoel Rosenblatt
Joel Rosenblatt
RPRandall Prince
Randall Prince
IRIssam Raad
Issam Raad
Fluoroquinolones are used for infection prevention in high-risk patients with haematological malignancies. Fluoroquinolones are active against many Gram-negative bacilli (GNB) but are less active against Gram-positive organisms. We evaluated the in vitro activity of delafloxacin and selected comparators against 560 bacterial pathogens isolated exclusively from patients with cancer. Antimicrobial susceptibility testing and time-kill studies were performed using CLSI-approved methodology and interpretive criteria for 350 Gram-positive organisms and 210 GNB that had been recently isolated from patients with cancer. Delafloxacin was more active than ciprofloxacin and levofloxacin against Staphylococcus aureus and CoNS. Overall, 63% of staphylococcal isolates were susceptible to delafloxacin, 37% to ciprofloxacin and 39% to levofloxacin. Activity of delafloxacin against most Enterobacterales was similar to that of ciprofloxacin and levofloxacin. Escherichia coli and MDR Pseudomonas aeruginosa isolates had low susceptibility rates to the three tested fluoroquinolones. In time-kill studies delafloxacin and levofloxacin decreased the bacterial load to 3.0 log10 in 8 and 13 h, respectively, using 8 × MIC. Delafloxacin is more active than ciprofloxacin and levofloxacin against S. aureus but has substantial gaps in coverage against GNB. Resistance to all three fluoroquinolones could be high among leading GNB such as E. coli and P. aeruginosa, particularly in cancer centres where these agents are widely used as prophylactic agents.

5 March 2024 in JAC-Antimicrobial Resistance
Verified
Journal Article
Open access
PDF file
BGBahgat Z Gerges
Bahgat Z Gerges
JRJoel Rosenblatt
Joel Rosenblatt
YTY-Lan Truong
Y-Lan Truong
YJYing Jiang
Ying Jiang
SSSamuel A. Shelburne
Samuel A. Shelburne
Issam I RaadIssam I Raad
Issam I Raad
Taniborbactam is a β-lactamase inhibitor that, when combined with cefepime, may offer a potential treatment option for patients with serious and resistant Gram-negative bacterial (GNB) pathogens. This study evaluated in vitro activity of cefepime/taniborbactam and comparator agents against GNB pathogens isolated from patients with cancer at our institution. A total of 270 GNB pathogens (2019–23) isolated from patients with cancer were tested against cefepime/taniborbactam and comparator agents commonly used for these patients. CLSI-approved broth microdilution methods were used. MIC50, MIC90, MIC range and percentage of susceptibility calculations were made using FDA breakpoints when available. Cefepime/taniborbactam showed highly potent activity against tested Enterobacterales, including isolates producing ESBLs and carbapenem-resistant Enterobacterales. At a provisional breakpoint of ≤16/4 mg/L, cefepime/taniborbactam inhibited most tested species of GNB pathogens, with overall 98.9% susceptibility, which was significantly (P < 0.0001) higher than the susceptibility of the GNB isolates to all other tested comparator agents, ranging from 39.6% for cefepime to 86.3% for ceftazidime/avibactam. Our results showed that taniborbactam in combination with cefepime improved in vitro activity against GNB pathogens isolated from patients with cancer, including MDR Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales, ESBL-producing Enterobacterales and Stenotrophomonas maltophilia isolates, with highest activity compared with all tested comparator agents, including other β-lactam/β-lactamase inhibitor combinations. Further studies are warranted to explore the efficacy of cefepime/taniborbactam for empirical initial treatment of GNB infections in cancer patients with high rates of febrile neutropenia requiring hospitalization.

24 February 2025 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
BGBahgat Z Gerges
Bahgat Z Gerges
JRJoel Rosenblatt
Joel Rosenblatt
YTY-Lan Truong
Y-Lan Truong
Ying JiangYing Jiang
Ying Jiang
Issam I RaadIssam I Raad
Issam I Raad
Candida colonization and biofilms are significant contributors to impaired wound healing. Consequently, improved treatments are needed to eradicate Candida biofilms in wounds. Wounds present complex biofilm extracellular matrix environments, with microbial cells frequently enmeshed in matrices comprising wound exudate macromolecular gels. We evaluated the ability of a polygalacturonic and caprylic acid (PG + CAP) ointment to eradicate Candida albicans, C. parapsilosis, C. glabrata, C. tropicalis, and C. auris biofilms in a fibrin gel wound biofilm model of the complex wound biofilm environment. Hypochlorous acid (HOCl) is a disinfecting antimicrobial agent that is widely used as wound irrigant, and this was used as a comparator. A single treatment with PG + CAP reduced the number of viable organisms in the C. albicans and C. glabrata biofilms by over 5 log10, in the C. parapsilosis and C. auris biofilms by over 4 log10, and in the C. tropicalis biofilm by 3.85 log10. PG + CAP was superior (p < 0.01) to HOCl in eradicating all Candida species biofilms, except for C. auris, for which both treatments fully eradicated all viable organisms. The use of HOCl in Candida-colonized wounds should include consideration of the extracellular matrix load in the wound bed. PG + CAP warrants further study in wounds compromised by Candida biofilms.

1 November 2023 in JAC-Antimicrobial Resistance
Verified
Journal Article
Open access
PDF file
BGBahgat Z Gerges
Bahgat Z Gerges
JRJoel Rosenblatt
Joel Rosenblatt
SSSamuel A. Shelburne
Samuel A. Shelburne
ACAnne-Marie Chaftari
Anne-Marie Chaftari
RHRay Hachem
Ray Hachem
Issam I RaadIssam I Raad
Issam I Raad
Tebipenem is a broad-spectrum orally administered carbapenem antibiotic that could be an alternative to IV carbapenems. The current study evaluated in vitro activity of tebipenem against bacterial isolates recovered from patients with cancer. A total of 611 bacterial pathogens recently isolated from patients with cancer were tested for susceptibility to tebipenem and comparators. CLSI-approved broth microdilution methods were used. MIC50, MIC90, MIC range and percentage susceptibility calculations were made using FDA breakpoints when available. Tebipenem had a low MIC90 for most Gram-positive and Enterobacterales isolates. Tebipenem MIC90 ranged from 0.06 to 0.25 mg/L for all tested Enterobacterales. Oral tebipenem has promising activity against clinically significant bacterial pathogens isolated from patients with cancer. Further clinical evaluation of tebipenem for the treatment of bacterial infections in patients with cancer is warranted.